BioInvent plans BI-1808 triplet trial in platinum-resistant ovarian cancer for Q1 2027

• BioInvent will present updated BI-1808 combination data in platinum-resistant recurrent ovarian cancer at ESMO on October 24, 2026.
• The abstract repeats Phase 1/2a results presented at ASCO 2026; the upcoming poster will include more patients.
• BI-1808 with pembrolizumab produced durable tumor responses, including complete remission, with few treatment-related discontinuations.
• A planned randomized study will evaluate BI-1808 with pembrolizumab and weekly paclitaxel, with or without bevacizumab.
• The study is expected to start in the first quarter of 2027, with initial data in the second half, subject to enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.